CD274 and posterior cortical atrophy: Although immunotherapy is not a commonly used treatment for PCa and several clinical trials ended in failure, pembrolizumab showed promising therapeutic efficacy irrespective of PD-L1 expression level for PCa patients with bone-predominant metastasis (KEYNOTE-199) [52].